Pentadecapeptide Arginate (PDA)
Pentadecapeptide Arginate, or PDA, is a synthetic peptide related to BPC-157. The pharmacy dispenses it as a compounded 10mg/mL injectable in two vial sizes. Compounded medications are not FDA-approved, and it is prescribed only after a licensed provider reviews your history.
Pharmacy shipping: $20 added once per medication order.
About this treatment
Understand the preparation behind the PDA name.
PDA is the name IAM uses for pentadecapeptide arginate, an injectable related to BPC-157. A useful consultation starts with the exact preparation and the injury, discomfort or recovery concern you want your clinician to assess.
A specific compounded injectable
IAM's catalog describes PDA as an arginate form related to the 15-amino-acid peptide BPC-157. The exact ingredient identity and formulation matter when evaluating a prescription. Ask the dispensing pharmacy to confirm what the product contains, its intended injection route and its handling instructions, especially if you have previously used a product with a different name.
Why it comes up in recovery conversations
The related BPC-157 research explores how tissue-repair cells move, survive and communicate. That background explains the interest in this family of compounds. For your care, the starting point remains the actual problem: where it hurts, how it began, and how it affects movement or daily activity. A clear diagnosis gives a recovery discussion a practical direction.
Keep function at the center of follow-up
For a tendon or overuse concern, describe which movements provoke symptoms and what you can comfortably do. Ask how rehabilitation, changes in activity and any other treatment fit together. Agree on what should be reassessed if pain worsens or function changes, with practical goals such as comfortable movement and a gradual return to your usual activity.
Research and product information
Direct human clinical evidence for pentadecapeptide arginate was not identified. Research on BPC-157, including laboratory tendon work, does not establish benefits or safety for this distinct arginate preparation. The compounded injectable is not FDA-approved.
- Chang et al. BPC-157 and tendon-cell behavior in laboratory models (2011)
- FDA: understanding compounded drug preparations
- NIH MedlinePlus: tendon symptoms, assessment and care
Sources checked .
Your path to Pentadecapeptide Arginate (PDA)
Complete the assessment
Share your health, training, and wellness goals in the patient portal.
Provider review
A licensed provider decides whether PDA fits your situation and what to prescribe.
Care coordination
Your care team coordinates the prescription and dosing supplies after provider approval.
About this treatment
What it is
PDA is a 15-amino-acid peptide, an arginate salt form related to BPC-157. IAM dispenses it as a compounded injectable. Research on it is early, and your provider will go over what is and is not known before prescribing.
Who it's for
Adults whose provider decides it fits after reviewing their history and current medications. Ask your provider whether it belongs in your plan.
Forms we dispense
Injectable 10mg/
A licensed provider reviews your history and requests labs when clinically appropriate before prescribing.
Prescriptions are coordinated with our licensed US pharmacy partner, with dosing supplies included when needed.
We do not sell pharmaceuticals online. Every prescription comes after a full provider review.
